Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of treatment resistant partial epilepsy;~* History of epilepsy for at least 2 years;~* Have at least 3 simple partial with motor component, complex partial or secondarily generalized seizures per month with no consecutive 21 day seizure free period.~* Currently treated on a stable dose of :~  * 1 - 3 AED's for at least 12 weeks prior to randomization.~ * VNS will not be counted as AED; however the parameters must remain stable for at least 4 weeks prior to baseline.~ * Benzodiazepines taken at least once per week for epilepsy, or for anxiety or sleep disorder, will be counted as 1 AED. Therefore only a maximum of two additional approved AEDs will be allowed.~Exclusion Criteria:~1. A history of alcoholism, drug abuse, or drug addiction within the past 2 years.~2. Subject has had status epilepticus within past 1 year.~3. Subject has had greater than 2 allergic reactions to an AED or one serious hypersensitivity reaction to an AED.~4. Subjects taking felbamate with less than 18 months continuous exposure.~5. Subjects receiving phenytoin, phenobarbitone or metabolites of these drugs.~6. No active suicidal plan/intent or active suicidal thoughts in the past 6 months.~7. History of suicide attempt in the last 2 years; not more than 1 lifetime suicide attempt.~8. Subject meets criteria for current major depressive episode (within 6 months).~9. Use of intermittent rescue benzodiazepines more than once/month (1-2 doses in a 24-hour period is considered one rescue) in the one month period prior to Visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- YKP3089 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).